Comparative Pharmacology
Head-to-head clinical analysis: GENOSYL versus GENTAMICIN SULFATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GENOSYL versus GENTAMICIN SULFATE.
GENOSYL vs GENTAMICIN SULFATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Genosyl (sodium phenylbutyrate) is a prodrug that is metabolized to phenylacetate, which conjugates with glutamine via acetylation to form phenylacetylglutamine. This alternative pathway facilitates waste nitrogen excretion in patients with urea cycle disorders.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting protein synthesis. Also disrupts bacterial cell membrane integrity.
5 mg orally once daily for 14 days, then 2.5 mg orally once daily thereafter.
1-2 mg/kg IV every 8 hours or 3-5 mg/kg IV every 24 hours for extended-interval dosing; typical duration 7-10 days.
None Documented
None Documented
Terminal half-life 3.5 hours; clinically relevant for dosing every 6-8 hours in renal impairment.
Terminal elimination half-life: 2-4 hours in patients with normal renal function; prolonged to 24-72 hours in renal impairment.
Renal: 85% unchanged; biliary/fecal: 15% as metabolites.
Renal excretion of unchanged drug accounts for >90% of elimination; biliary/fecal <2%.
Category C
Category D/X
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic